Abstract 142P
Background
Pancreatic cancer (PC) remains a major health concern due to its dismal prognosis and high mortality rates. Hypoxia-inducible factor 1-alpha (HIF-1α) is implicated in promoting tumor growth, angiogenesis, and metabolic changes under hypoxic conditions. However, an all-inclusive understanding of HIF-1α's precise role and clinical impact on PC is yet to be ascertained. This study aims to study the influence of HIF-1α on PC. Specifically, the goal is to assess differences in overall survival (OS) and OS in the context of metastasis between PC patients with high and low expression of HIF-1α.
Methods
We comprehensively searched PubMed, Embase, and the Cochrane Library databases for relevant research articles published until December 2022. Studies eligible for inclusion compared clinical outcomes in PC patients expressing high and low levels of HIF-1α. Primary outcomes of interest were OS and OS in patients with metastasis, computed using the hazard ratio (HR). The R software (version 4.0.3) with metafor and meta packages was used for all statistical analyses, utilizing random-effects models.
Results
Our meta-analysis encompassed 16 studies, representing a cohort of 1,080 PC patients, including 566 with high HIF-1α expression and 514 with low HIF-1α expression. The pooled HR for OS was 1.86 (95% CI: 1.64-2.12, P<0.01, I2=0%), indicating significantly lower survival rates among patients expressing high HIF-1α. More crucially, the pooled HR for OS in patients with metastasis was 2.09 (95% CI: 1.67-2.64, P<0.01, I2=0%), suggesting an even poorer survival outcome in metastatic PC patients with high HIF-1α expression.
Conclusions
Our findings highlight the considerable prognostic role of HIF-1α in PC, particularly elucidating its fundamental role in disease progression and prognosis, especially in the context of metastasis. These insights could stimulate the development of innovative therapeutic strategies that target HIF-1α, with potential implications for enhancing survival rates in PC patients. Further studies should validate these findings in larger, prospective cohorts and further investigate the specific mechanisms through which HIF-1α exacerbates PC progression, particularly in metastatic cases.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract